May 2026 in “Pharmaceuticals” This study analyzed safety data for semaglutide, liraglutide, and tirzepatide from the EudraVigilance database, identifying potential safety signals not listed in current SmPCs, such as optic ischemic neuropathy and pancreatitis, underscoring the importance of ongoing pharmacovigilance.
September 2026 in “Problems of Endocrinology” This article discusses the prevalence and mechanisms of hair loss associated with weight loss treatments and reports no new clinical results; it emphasizes the need for prevention and management strategies in affected patients.
January 2026 in “Research Square (Research Square)” This systematic review reports that HAIR-AN syndrome, characterized by severe insulin resistance, hyperandrogenism, and distinctive skin issues, significantly impacts obese women and can improve with treatments like metformin, emphasizing the importance of targeted management to reduce metabolic complications.
4 citations
,
January 2019 in “Therapeutic Advances in Endocrinology and Metabolism” This review found no evidence that medications used to manage PCOS add to cardiovascular risk or prevent diabetes onset, although metformin may help prevent gestational diabetes in these patients.
34 citations
,
September 2020 in “BMC Endocrine Disorders” This review highlights that while dexamethasone may reduce mortality in severe COVID-19, no other drugs have proven effectiveness for treatment, emphasizing the need for clinical trials of existing medications.
